This post is authored by Tricia Rodriguez, senior applied scientist, Truveta Research.
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is gearing up for a fantastic event, slated for May 7-10, 2023, in Boston. As an applied scientist with Truveta Research, I am particularly excited about this year’s conference, which is focused on groundbreaking advancements in the field of health economics and outcomes research (HEOR).
One of the things that excites me about this year’s conference is the increased focus on combining emerging technologies with real-world data to impact healthcare outcomes. The healthcare industry is undergoing a major transformation because of advances in technology, and the HEOR community is at the forefront of this shift. The conference will provide an opportunity to explore the potential of technologies such as AI and machine learning to drive better outcomes and reduce costs in healthcare.
As someone who has presented at ISPOR in the past, focused on risk prediction in cystic fibrosis and in colorectal cancer recurrence using real-world data, I am particularly proud to present work from Truveta Research this year. Our work, in partnership with a collaborator at Providence, focuses on the comparative effectiveness of SGLT2i in type 2 diabetes. This is the first comparative effectiveness study Truveta Research has presented at a research conference. To have the opportunity to present research on behalf of Truveta and Providence is a great example of the power of our partnership with our health system members.
Three things I’m looking forward to at ISPOR this year
Presenting work from Truveta Research
I’ve presented at ISPOR in the past, but this year I’m particularly proud to present work from Truveta Research. In partnership with a collaborator at Providence, our work from Truveta Research focuses on the comparative effectiveness of SGLT2i in type 2 diabetes. This is the first comparative effectiveness study Truveta Research has presented at a research conference.
This year’s event is a celebration of research excellence and innovation. I am proud to present our research on the comparative effectiveness of SGLT2i in type 2 diabetes, a first-of-its-kind study from Truveta Research in partnership with Providence. To have the opportunity to present research on behalf of Truveta and Providence is a great example of the power of our partnership with our health system members.
But that’s not all. Our team has made other impactful insights include:
Hearing from peers about their work with RWE
The conference brings together a diverse group of professionals from around the world, including researchers, clinicians, payers, and policymakers. The opportunity to exchange ideas and collaborate with others in the field is invaluable for advancing the science of HEOR. I’m looking forward to hearing from my peers about their work with real-world evidence (RWE), learning about novel methods for studies using real-world data (RWD), and seeing the latest research on health and economic outcomes of new treatments and therapies for a range of conditions, including chronic diseases, mental health disorders, and rare diseases.
Learning about novel methods for studies using RWD
Finally, I’m excited to see the latest research on health and economic outcomes of new treatments and therapies for a range of conditions, including chronic diseases, mental health disorders, and rare diseases. The HEOR community plays a critical role in evaluating the health and economic outcomes of these treatments and ensuring that they are accessible to patients who need them. Real-world data are increasingly important for these evaluations. ISPOR 2023 will showcase the latest research in this area and provide an opportunity to learn about new treatments and therapies that are on the horizon.
ISPOR 2023 is shaping up to be a groundbreaking event for the field of HEOR. With a focus on emerging technologies, patient-centered care, collaboration, and the latest HEOR research on new treatments and therapies, attendees are sure to leave the event with new insights and ideas for advancing the field and improving health outcomes for patients around the world. Truveta Research is excited about the opportunity to hear about what others are working on to identify potential partnerships and applications of Truveta Data to advance research given the timeliness and scale of our data.
You can find out more about my research poster session on Tuesday, May 9 from 9:45am – 1:15pm at ISPOR by clicking on this link: Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin As First-Line Therapy in Type 2 Diabetes.